Pheochromocytoma

Karel Pacak is a professor who established the Pheochromocytoma Research Program at the NIH, one of the most prestigious and largest programs worldwide, and has published over 80 articles/book chapters on this topic. He has Introduced new biochemical and imaging approaches to this tumor, especially the use of 18F-fluorodopamine in localization of pheochromocytoma. He also developed new biochemical and imaging algorithms for pheochromocytoma for practicing physicians. Moreover, developed new animal model of metastatic pheochromocytoma. Currently working as the Chief of Section on Medical Neuroendocrinology, NICHD. He is also Professor of Medicine at Georgetown University, Washington DC and Charles University, Prague, Czech Republic. Graham Eisenhofer is a clinical biochemist with broad experience in basic and patient-oriented research on neuroedocrine and autonomic nervous system function in health and disease. Relevant achievements include codevelopment with Dr. Jacques Lenders of the first HPLC method for measurements of plasma free metanephrines, a test now used for improved biochemical diagnosis of pheochromocytoma. Dr. Eisenhofer was also responsible for initial development of 18F-fluorodopamine as a positron emission tomographic imaging agent for visualizing sympathetic nerves and neuroendocrine tumors. Dr. Eisenhofer co-chairs the Pheochromocytoma RESearch Support ORganization.

• Introduction: Karel Pacak and Graeme Eisenhofer. Part I: Pheochromocytoma: A Kaleidoscope of Presentations and a Minefield for Differential Diagnosis: 1. Diagnostic Challenges and Vagaries of Pheochromocytoma: William M. Manger.2. Clinical Characteristics of Incidentally-Discovered Pheochromocytoma Based on Experience in 50 Proven Cases: Emmanuel L. Bravo.3. Clinical Experience with 1080 Adrenal Incidentalomas Observed at a Single Endocrinological Center: A Place for Chromaffin Tumors: Anna Kasperlik-Zaluska.4. Characteristics of pheochromocytoma in a 4- to 20-year-old population: Marta Barontini.5. Pheochromocytoma During Pregnancy: A Literature Survey: Henri Timmers.6. Lack of Symptomatology in Patients with Histological Evidence of Pheochromocytoma: A Diagnostic Challenge: Debbie L. Cohen.Part II: Genetics: Increasing Importance for Clinical Decision-Making:.7. Predictors and Prevalence of Paraganglioma Syndrome Associated with Mutations of the SDHC Gene: Hartmut Neumann.8. Genetic Analysis of Pheochromocytoma: The Rotterdam Experience: Winand N.M. Dinjens.9. Molecular Genetic Analysis of the NF1 Gene in Neurofibromatosis-Associated Pheochromocytoma: Birke Bausch.10. Candidate Gene Mutation Analysis in Pediatric Pheochromocytomas: Ronald R. de Krijger.11. Familial Non-Syndromic Pheochromocytoma: Giuseppe Opocher.12. Genetic Mutation Screening in an Italian Cohort of Non-Syndromic Pheochromocytoma/ Paraganglioma Patients: Maurizio Castellano.13. Importance of SDHB Mutation Testing in Patients with Malignant Pheochromocytoma: Frederieke Brouwers.Part III: Pheochromocytoma/Paraganglioma Syndromes:.14. Paragangliomas: Clinical Overview: William F. Young, Jr.15. Genetics of Pheochromocytoma/Paraganglioma Syndromes: Anne-Paule Gimenez-Roqueplo.16. SDHD, SDHB Mutations: Different Phenotype and Penetrance (International SDH Consortium): Diana Benn.17. Mutational Spectrum of Paragangliomas Obtained from Archival Paraffin Sections: Jeffrey Kant.18. Sporadic SDHB Mutation in an Extra-Adrenal Pheochromocytoma: Francien H. Van Nederveen.19. SDHD Founder Mutation in Italian Families with Head and Neck Paraganglioma: Francesca Schiavi.Part IV: Tumor Biology, Molecular Pathways of and Genotype/Phenotype Relationships:.20. Role of Familial Pheochromocytoma Genes in Developmental Culling of Sympathetic Progenitors: William Kaelin.21. RET Receptor Signalling: Dissecting Receptor Function and Dysfunction: Lois Mulligan.22. Hereditary Paraganglioma: An Emerging Link Between Krebs Cycle and Hypoxic Signaling: Bora E. Baysal.23. Linking Hypoxia and Redox Signals in Pheochromocytoma: Transcription Association of VHL and SDH Mutations: Patricia Dahia.24. Expression of mRNAs for Succinate Dehydrogenase Subunits and Related Genes in Pheochromocytoma: Kazumasa Isobe.25. Low SDHB Expression by Immunohistochemistry Discriminates Pheochromocytoma with SDHB, SDHD and VHL Mutations from Other Hereditary Forms: Sandro Santagata.26. Mouse Pheochromocytoma Cell Lines Reveal Transcriptional Silencing of Adrenergic Phenotype by Neurotrophin and cAMP: Marian J. Evinger.Part V: Biochemical Diagnosis and Tumor Localization:.27. Plasma Free Metanephrines for Diagnosis of Pheochromocytoma: False Positives and Effects of Sampling Conditions: Jacques W.M. Lenders.28. Advancements in Biochemical Diagnosis of Pheochromocytoma: Ravinder Singh.29. Multicenter Study on the Diagnostic Value of a New RIA for the Detection of Free Plasma Metanephrines in the Work-Up for Pheochromocytoma: Tomas Lenz.30. Diagnostic Value of Plasma and Urinary Metanephrines and Catecholamines for the Diagnosis of Pheochromocytoma in Patients with Adrenal mass: Stephan Petersenn.31. Evolving Role of PET Imaging for Diagnostic Localization of Pheochromocytoma: Karel Pacak.32. Elusive Pheochromocytomas: Detection with Functional Imaging Using MIBG and FDG PET: Barry L. Shulkin.Part VI: Management and Treatment of Pheochromocytoma:.33. Risk-Oriented Surgical Approach to Hereditary Pheochromocytoma: Henning Dralle.34. The Course of Urinary Metanephrine Excretion in Recurrent and Malignant Pheochromocytoma: Pierre-Francois Plouin.35. Mortality Associated with Pheochromocytoma: Increased Risk of Additional Tumors: Amir Khorram-Manesh.36. Clinical Analysis and Management of Pheochromocytoma: Experience from 360 Cases in Peking Union Medical College Hospital (PUMCH), Beijing, China: Zheng-pei Zeng.37. Magnesium Sulfate in the Perioperative Management of Pheochromocytoma: Michael F. James.38. Treatment of Bilateral Pheochromocytoma and Adrenal Medullary Hyperplasia: Svante Jansson.Part VII: Malignant Pheochromocytoma:.39. Phase II Study of High-Dose 131I-MIBG Therapy for Patients with Malignant Pheochromocytoma and Paraganglioma: Paul A. Fitzgerald.40. 131I-MIBG Radiotherapy: Long-term Experience with Treatment of Malignant Pheochromocytoma and Paraganglioma: Jon P. Gockerman.41. AT2 Receptor Stimulation May Halt Progression of Pheochromocytoma: Morris J. Brown.42. Can Quantification of VMAT and SSTR Expression be Helpful for Planning Radionuclide Therapy of Malignant Pheochromocytomas: Lars Kölby.43. Development of Novel Tools for the Diagnosis and Prognosis of Pheochromocytomas Using Peptide Marker Immunoassay and Gene Expression Profiling Approaches: Youssef Anouar.44. Gene Expression Profiling of Benign and Malignant Pheochromocytoma: New Markers for Prognosis and Targets for Treatments: Peter Munson & Graeme Eisenhofer